Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update
Quince Therapeutics reported Q2 financial results highlighted by the completion of the Orphai Therapeutics acquisition and a $115 million private placement financing. The company ended the quarter with $116 million in cash, which is expected to fund operations through the end of 2028, supporting the development of the LAM-001 pipeline.
Key figures
- Runway
- end of 2028
- Net loss
- $75.5 million
- Ga expense
- $16.6 million
- Rd expense
- $5.5 million
- Proceeds net
- $103.6 million
- Cash position
- $116 million
- In process rd
- $59 million
- Proceeds gross
- $115 million
- Warrants potential
- $83 million
- Reverse split ratio 1
- 1-for-10
- Reverse split ratio 2
- 1-for-20
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.